Please login to the form below
Valeant
This page shows the latest Valeant news and features for those working in and with pharma, biotech and healthcare.
AbbVie lauds head-to-head win for Skyrizi versus Cosentyx
Cosentyx, Skyrizi and Tremfya face increasing competition in the psoriasis market however, with a host of other new entrants including Eli Lilly’s Taltz (ixekizumab), Leo/Valeant’s Siliq (brodalumab) and
Latest news
-
Shire bags US approval for constipation drug Motegrity
Bausch Health (formerly Valeant) has just launched a bid for the company on the premise that it will be able to kick start sales of Trulance, Synergy’s only-approved product,
-
J&J takes on Novartis’ Cosentyx with head-to-head psoriasis trial
Cosentyx was the first IL-17 inhibitor to reach the market and, while it has since been joined by rivals from Eli Lilly (Taltz) and Valeant (Siliq), is well ahead in
-
Daily Brief: Andrew Witty's replacement on Accelerated Access initiative, Blincyto gains full EU approval and more
Valeant shares tumble after FDA rejection. A rejection by the US regulator for Valeant’s plaque psoriasis treatment. ... Valeant said in a statement that the FDA had not specified any clinical efficacy or safety shortcomings in its Complete Response
-
UK, Germany back routine use of J&J’s Tremfya
Add in additional IL-17 inhibitors for Eli Lilly and Valeant and the market for biologics for psoriasis is looking increasingly crowded, and a lot will depend on which of the
-
Daily Brief: Deal done, Takeda to cut $1.4bn, Brexit latest, Valeant rebrands
Looking to distance itself from toxic past, Valeant to rebrand as Bausch Health. ... Valeant’s years of buccaneering mergers and acquisitions, suspect business practices and allegations of fraud have left it saddled with debt and a pariah-like status
More from news
Approximately 46 fully matching, plus 98 partially matching documents found.
Latest Intelligence
-
Pharma deals continue to slide
$35bn. $7.3bn. Valeant. 40. 17.5. -56%. $28bn. ($2.4bn). Perrigo. 90. 78. ... Perrigo, like Teva and Valeant, is seeking to reduce debt. Biotech companies are also selling (or licensing) assets to stay alive.
-
Deal Watch - May 2017
It is likely that in the next few months companies such as Teva and Valeant that are having a difficult time at the moment will divest parts of their business.
-
Deal Watch March 2017
There are more below the radar (without accompanying numbers), for example: Valeant has granted Glycyx a sublicence to develop products containing methylnaltrexone bromide for oncology indications, and Fuji Pharma has obtained
-
Deal Watch January 2017
Bringing in an additional $819.9m in cash, Valeant also sold its equity interest in Dendreon (manufacturer of Provenge, a personalised immunotherapy) to the Sanpower Group. ... 1, 600. Valeant. L'Oreal. Divestment. CeraVe AcneFree AMBI. 1, 300. Forward
-
Deal Watch August 2016
Finally it was interesting to see that Pharming has recovered from Valeant the North American rights to its product Ruconest. ... Pharming did well to get the rights back especially as it resulted in Valeant having to make a $199m write down of its
More from intelligence
Approximately 1 fully matching, plus 31 partially matching documents found.
Latest appointments
-
ThermiGen appoints Vladimir Paul-Blanc as president
He previously served Solta Medical - the aesthetics energy device division of Valeant Pharmaceuticals – as its general manager.
-
BMS appoints three independent directors
Robert Bertolini brings strategic and operational leadership experience from Bausch &Lomb, where he recently served as president and chief financial officer prior to the company's sale to Valeant.
-
Valeant appoints Joseph Papa to end CEO uncertainty
Valeant's month-long search for a new chief executive has ended with its selection of Perrigo's Joseph Papa to replace current CEO Michael Pearson in early May. ... Searle &Company, Novartis and Pharmacia Corporation. He said: “I am excited to take on
-
Valeant adds member to board of directors
President of ValueAct Capital G. Mason Morfitadded to team. Valeant Pharmaceuticals has added G. ... Morfit had originally served on Valeant's board of directors between 2007 and 2014.
-
Valeant adds Robert Hale to board of directors
And Jeffrey Ubben resigns from the board. Valeant has added Robert Hale, a partner at ValueAct Capital, to its board of directors. ... He said: “I have had a wonderful experience serving as director of Valeant.
More from appointments
Approximately 6 fully matching, plus 10 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- Biogen and Happify Health team up to create digital platform for MS patients
- Moderna to launch Innovation and Technology Center in the UK
- Enanta takes legal action against Pfizer over Paxlovid patent infringement
- Novartis and Precision BioSciences announce in vivo gene editing collaboration
- Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine
- Why project managers are key to creating quality content
- Pfizer and BioNTech sign $3.2bn COVID-19 vaccine supply agreement with US government
- EMA grants Bavarian Nordic access to PRIME scheme for RSV vaccine candidate
- Eli Lilly to supply US government with 150,000 additional doses of bebtelovimab
- NICE issues final appraisal recommending LEO Pharma’s Adtralza for moderate-to-severe atopic dermatitis
- How Resonant’s innovation and creativity resolve healthcare communications challenges
- ALL SYSTEMS GO: UNDERSTANDING WHO’S WHO IN THE NEW NHS LANDSCAPE
- A creative awakening – how pharma is bringing innovation to the patient journey
- AstraZeneca’s Evusheld phase 3 results show high level of protection against COVID-19
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- Novartis endorses Kigali Declaration by investing $250m for tropical diseases
- Pfizer, Mylan move ahead with generics merger and spin-out
PMHub
ahair@onyxhealth.com
Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
